newsfilter
← Latest News
Business Wire·

MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy Lifespan

Key objective of the trial is to reduce levels of the protein that causes inflammation and activates aging, TNF-α, in the blood MYMD-1 is designed to become the first and only FDA-approved therapeutic solution for delaying aging and prolonging life